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Abstract
Multiple diagnostic approaches are available for Clostridium difficile infection (CDI); current guidelines support two-step testing (2ST) as the
preferred approach. We retrospectively evaluated the impact of switching from toxin enzyme immunoassay (EIA) to 2ST, and then to
polymerase chain reaction (PCR), on CDI rates, test utilization and CDI treatment at a 900-bed tertiary care community teaching hospital.
All inpatients tested for CDI between December 2008 and February 2011 were included. A positive toxin EIA or PCR was diagnostic of
CDI; 2ST was performed using glutamate dehydrogenase EIA, followed by PCR if positive. Repeat tests within 8 weeks on the same patient
were considered part of the same testing episode. Data were collected electronically and studied in aggregate from 9725 unique inpatients
tested for CDI, representing 20 836 individual tests. PCR detected 41% more patients with CDI than toxin EIA (p <0.0001), and 15% more
than 2ST (p 0.02), corresponding to higher hospital-onset and community-onset CDI rates. The number of CDI tests performed per patient
decreased by 48% with PCR (p <0.0001) compared with toxin EIA. For patients with CDI, time to the first positive test result was shortest
with PCR. For patients without CDI, a negative PCR, but not 2ST, was associated with 22% fewer CDI treatment days, compared with toxin
EIA (p <0.0001). Compared with both toxin EIA and 2ST, PCR detected more CDI patients faster and with less frequent testing, and
negative PCR results were associated with less empirical CDI treatment.
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Introduction
Clostridium difficile infection (CDI) incidence and severity have
reached historic levels, yet optimal testing approaches remain
unclear and pose a barrier to timely and reliable diagnosis
[1–3]. Current Infectious Diseases Society of America
guidelines endorse two-step testing (2ST) over toxin enzyme
immunoassay (EIA) for the diagnosis of C. difficile infection
[4]. However, despite its poor sensitivity [2,5], toxin EIA
remains the primary diagnostic test for most hospitals
because it is inexpensive, simple to perform and yields quick
results [1].
The effect of more sensitive CDI testing methods on clinical
treatment decisions, laboratory resource utilization, infection
control practices and publicly-reported CDI rates is not well
described. Although polymerase chain reaction (PCR) testing is
regarded as highly sensitive and specific for CDI [6], guidelines
have cited a need for more data prior to fully embracing PCR
over 2ST [4]. For quality improvement purposes, we switched
from toxin EIA to 2ST, and then to exclusive PCR testing. We
describe the impact of these testing changes on CDI rates, test
utilization and clinical treatment.
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Methods
Cedars-Sinai Medical Center is a 900-bed acute tertiary care
community teaching hospital in Los Angeles, California. All
inpatients tested for CDI between December 2008 and
February 2011 were included. A CDI episode was defined as
a patient with a positive toxin EIA or PCR. Testing for CDI was
performed at the discretion of the attending physician; no
chart review was conducted to assess for CDI symptoms, and
testing was not restricted to unformed stool specimens. All
repeat CDI tests performed for the same patient within
8 weeks of the initial test were attributed to the same CDI
testing episode. Community-onset (CO) CDI was defined as a
patient with a positive CDI test within the first 3 days of
admission; we did not distinguish community-onset, healthcare
facility-associated CDI as defined by IDSA guidelines [4]. All
CDI patients testing positive after hospital day 3 were
considered to have hospital-onset (HO) CDI.
Between December 2008 and November 2009, patients
were tested for CDI with toxin A/B EIA (Meridian Bioscience
Inc, Cincinnati, OH, USA), and physicians commonly ordered
three tests per diarrhoeal episode. From December 2009 to
April 2010, CDI testing changed to 2ST. This consisted of an
initial test with glutamate dehydrogenase (GDH) EIA (Alere
Inc, Waltham, MA, USA); positive tests were confirmed with
molecular testing for tcdB by PCR (GeneXpert; Cepheid,
Sunnyvale, CA, USA). Results of GDH EIA and PCR (if
performed) were reported simultaneously, and laboratory
reporting of positive GDH EIA results directed clinicians to
refer to PCR results for diagnosis. Physician education
regarding CDI testing changes was provided through grand
rounds, written communication and other educational forums,
and repeat testing for the same diarrhoeal episode was
discouraged. Beginning May 2010, PCR was used exclusively,
and repeat CDI tests within 1 week were cancelled by the
laboratory per hospital policy.
Admission dates, CDI test results, demographic informa-
tion, antibiotic usage and colectomy procedures were elec-
tronically collected and studied in aggregate for each testing
period. Inpatient days were calculated, excluding neonates.
CDI treatment days were calculated as the number of days on
metronidazole (oral or intravenous) or oral vancomycin within
15 days of the initial CDI test collection. Antibiotic usage data
were available from August 2009. No clinical chart review was
performed. All statistical calculations (chi-squared, t-tests,
Wilcoxon rank sum and Kruskal–Wallis tests) were per-
formed using SAS v9.2. This study was reviewed by our
institutional review board and exempted from requiring
informed consent.
Results
A total of 9725 unique patient testing episodes, accounting for
20 836 individual C. difficile tests, occurred for inpatients
during the study period; 36 PCR results were excluded due to
indeterminate results (inhibitory substances). Patient demo-
graphics, overall length-of-stay and the number of unique
patients tested per day were no different across the three
testing periods (Table 1).
Patients with CDI
With toxin EIA testing, 14.2% of unique patients tested for
CDI had a positive test result. This proportion increased to
17.5% with 2ST (23.2% increase, p 0.001). With PCR, 20.0% of
unique patients tested were positive, representing a 41.1%
increase compared with toxin EIA (p <0.0001) and a 14.6%
increase compared with 2ST (p 0.02).
The increased 2ST and PCR test sensitivity was associated
with differences in both HO and CO CDI rates. Compared
with a HO CDI rate of 12.88 cases per 10 000 patient days
with toxin EIA, rates were higher with both 2ST (14.23 per
10 000 patient days, 10.6% increase, p 0.28) and PCR (15.63
per 10 000 patient days, 21.4% increase, p 0.01), though the
TABLE 1. Comparison of patient demographics, C. difficile
infection rates, testing characteristics and outcomes between
three C. difficile diagnostic testing approaches
Diagnostic test
Toxin
EIA 2ST PCR p value
#Unique patients tested for CDI 4205 1916 3604
Average age (years) 62.2 61.9 61.0 NS
% Female 51.6 51.3 51.5 NS
Average hospital LOS (days) 15.6 16.2 15.3 NS
Average # unique patients tested/day 11.6 11.9 12.1 NS
Average # CDI tests
performed/patient
2.70 n/a 1.39 <0.01
% Patients with only one CDI test 19.9 n/a 72.8 <0.01
% Patients with CDI 14.2 17.5 20.0  0.02a
HO CDI cases per 10 000
patient days
12.88 14.23 15.63 0.01b
CO CDI cases per 1000 admissions 4.73 6.76 8.42  0.03a
Patients with CDI (n) 597 335 722
Hours to first positive result
(median)c
32.3 26.5 17.0  0.01a
LOS after CDI diagnosis
(average days)
12.2 11.8 10.1 NS
Colectomies per 100 CDI cases 0.83 0.57 0.72 NS
Patients without CDI (n) 3608 1581 2882
Average # CDI treatment days 2.12 2.02 1.65  0.01d
% Receiving  4 days of
CDI treatment
25.0 22.8 18.7  0.01d
EIA, enzyme immunoassay; 2ST, two-step testing; PCR, polymerase chain reaction;
NS, not statistically significant (p >0.05); CDI, Clostridium difficile infection; LOS,
length of stay; HO, hospital onset; CO, community onset; GDH, glutamate
dehydrogenase; n/a, not applicable.
aSignificant difference observed between all groups (toxin EIA vs. 2ST, 2ST vs.
PCR, and toxin EIA vs. PCR).
bSignificant difference between toxin EIA and PCR only; p >0.05 for toxin EIA vs.
2ST, and 2ST vs. PCR.
cMeasured from the time of first specimen collection.
dSignificant difference between 2ST vs. PCR and toxin EIA vs. PCR only; p >0.05
for toxin EIA vs. 2ST.
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difference between 2ST and toxin EIA was not statistically
significant. Increases in CO CDI rates were also observed. The
rate of CO CDI with toxin EIA was 4.73 cases per 1000
admissions; it increased by 42.9% to 6.76 cases per 1000
admissions with 2ST (p 0.0003), and by 78.0% to 8.42 cases
per 1000 admissions with PCR (p <0.0001).
Testing frequency and time to first positive result
The average number of tests performed per patient decreased
from 2.70 with toxin EIA to 1.39 with PCR (48.4% reduction,
p <0.0001). The proportion of patients with CDI that had only
one test performed increased from 19.9% with toxin EIA to
72.8% with PCR. For patients with CDI, the median time from
submission of the first stool sample to report of the first
positive test was longest (32.3 h) with toxin EIA, decreased to
26.5 h with 2ST (18% reduction, p 0.0002), and further
decreased to 17.0 h with PCR (36% reduction compared with
2ST, p <0.0001).
Patients without CDI
Negative PCR was associated with decreased empirical CDI
treatment compared with negative toxin EIA results. The
average number of CDI treatment days decreased from
2.12 days (toxin EIA) to 1.65 days (PCR, 22.2% reduction,
p <0.0001), and the proportion of patients receiving 4 or more
days of CDI treatment decreased from 25.0% (toxin EIA) to
18.7% (PCR, p <0.0001). In contrast, negative 2ST was not
associated with a significant reduction in empirical treatment
compared with negative toxin EIA (2.02 average treatment
days, 22.8% received  4 CDI treatment days, p 0.26 and
p 0.17, respectively).
Patients with negative 2ST fall into two categories: those
with negative GDH EIA (n = 1456) and those with a positive
GDH EIA but negative PCR (n = 29). We observed that
patients with discordant results (positive GDH EIA but
negative PCR) received disproportionately more empirical
CDI therapy (58.6% received  4 days of treatment) com-
pared with those with negative GDH EIA results (22.0%,
p <0.0001).
Discussion
We found PCR to be more sensitive than either toxin EIA or
2ST in detecting patients with toxigenic C. difficile. PCR was
also associated with a shorter time to CDI diagnosis compared
with both toxin EIA and 2ST. Both the improved sensitivity and
faster diagnosis with PCR can be expected to have direct
clinical and infection control benefits. Additionally, we have
demonstrated that this improved sensitivity can reflect
increased nosocomial CDI rates, highlighting the importance
of accounting for hospital testing methodology when compar-
ing publicly reported hospital CDI rates, particularly as in the
US 51% of hospitals currently rely on toxin EIA testing [1].
The recent and dramatic rise in the worldwide incidence
and severity of CDI is complicated by high rates of misdiag-
nosis attributable to frequent use of suboptimal clinical tests,
commonly toxin EIA [7]. Both the IDSA [4] and the European
Society of Clinical Microbiology and Infectious Diseases
(ESCMID) [8] agree that toxin EIA testing alone is suboptimal,
and both societies propose two-step testing to improve
diagnostic accuracy. However, debate continues around the
role of 2ST versus PCR alone for diagnosis of CDI [2–5]. 2ST
often utilizes GDH EIA, which is fast and inexpensive, but
non-specific [9]. Unfortunately, data regarding the sensitivity of
GDH EIA-based 2ST are conflicting [10,11], which may in part
be due to regional differences in C. difficile ribotypes [12]. Our
results are consistent with other reports suggesting that GDH
EIA-based two-step algorithms are less sensitive than PCR
alone [11–13].
All three testing modalities considered here (PCR, GDH
EIA and PCR) have similar turnaround times (TATs) of a few
hours per each individual test. However, when multiple tests
are performed per patient (such as with 2ST, or as commonly
ordered with toxin EIA), a more clinically relevant measure
may be the time to first positive result, as measured from the
time of submission of the first clinical sample. Using this
measure, we observed that PCR had a faster time to a first
positive result than either toxin EIA or 2ST. There are two
potential explanations for this observation. First, patients
tested by toxin EIA commonly had >1 test performed
sequentially, delaying the diagnosis if the first positive test
was not the first test performed. Second, the transition to
PCR testing allowed our laboratory to test more frequently
(three times daily) than it had with toxin EIA or 2ST (once
daily). We suspect a combination of both factors contributed
to the shorter time to CDI diagnosis with PCR. A faster time
to first positive result has both clinical and infection control
benefits, because early diagnosis and prompt isolation can have
the most impact when environmental contamination (and risk
of nosocomial transmission) is highest [14].
We observed a 48% reduction in the number of tests
performed per patient with PCR compared with toxin EIA.
Although physician education to limit testing to only one PCR
per diarrhoeal episode may have played a role, we attribute
the majority of this reduction to the change in hospital policy
that allowed the microbiology laboratory to cancel repeat
tests within 1 week (exceptions were given for physicians who
communicated a change in patient clinical status to the
laboratory). This decline in test utilization is relevant because
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the increased cost of PCR is a barrier to wider implementa-
tion. Though we did not conduct a formal cost analysis, we
believe the reduction in test utilization with PCR mitigates the
increased cost.
As expected, more sensitive testing methods increased
both CO and HO CDI rates. However, we observed a
disproportionate increase in CO CDI rates compared with
HO rates with more sensitive testing methodologies. Catanz-
aro et al. made a similar observation, and attributed their
reduced HO to CO CDI ratio to improved infection control
practices resulting from faster and more accurate PCR testing
compared with toxin EIA [15]. Another explanation may be
that the disproportionate increase in CO CDI is an artifact of
its definition (testing positive on or before hospital day 3).
Sending multiple toxin EIA tests per patient may significantly
underestimate the prevalence of CO CDI, because repeat
testing increases the likelihood that the first positive result
comes from a stool collected >3 days after admission.
Without an assessment of the timing of symptom onset, we
cannot formally assess changes in the incidence of HO CDI. It
is therefore unclear which mechanism is responsible for our
observed disproportionate increases in CO CDI rates com-
pared with HO CDI rates.
In patients with a negative CDI test, PCR, but not 2ST, was
associated with a significant 22% reduction in average empirical
CDI treatment days compared with toxin EIA. This may reflect
the faster time to positive results with PCR, and possibly
increased clinician confidence in negative PCR results. Interest-
ingly, with 2ST we observed more empirical treatment in those
with a positive GDH EIA (but negative PCR), compared with
those with a negative GDH EIA (no PCR performed). This may
have been a consequence of simultaneously reporting the GDH
EIA and PCR results to clinicians. Although positive GDH EIA
results included laboratory comments directing clinicians to
refer to the PCR result for diagnosis, we suspect the lack of
further interpretation contributed to clinical confusion and
unnecessary treatment. This observation provides insight into
optimizing how 2ST results should be reported.
Our study’s strengths include a large sample size and a
real-world testing environment. To our knowledge, this is the
largest comparison of multiple CDI testing methodologies.
There are several limitations. First, the retrospective design
creates the possibility that differences in CDI rates between
the testing periods may reflect a change in local CDI
epidemiology. This is unlikely, given there was no difference
in the proportion of patients tested for CDI, or in indicators of
severe CDI between testing periods. Second, specific factors
at our single institution may reduce the generalizability of our
findings. Third, C. difficile ribotype information was not
available, which may affect GDH sensitivity [12].
A fourth limitation is that without chart review we were
unable to evaluate if increased CDI rates reflect increased
detection of asymptomatic colonization. This limitation is
true of all testing methodologies, as a positive clinical test
without associated symptoms does not necessitate treat-
ment [4]. This underscores the importance of clinical
discretion when ordering testing for CDI. Despite this
limitation, increased test sensitivity may still have infection
control benefits, as emerging evidence implies that asymp-
tomatic C. difficile colonization may significantly contribute to
nosocomial transmission [16]. Additionally, our findings
relating to increased nosocomial CDI rates remain relevant
to public reporting, as the LabID methodology used by the
National Healthcare Safety Network to report nosocomial
CDI rates also does not distinguish between colonization and
infection [1].
The absence of optimal testing approaches remains a barrier
to accurate and timely CDI diagnosis, posing limitations not
only for effective clinical management, but also for prevention
opportunities through infection control measures [3,7].
Despite the potential advantages we have identified with
PCR testing, it is important to note that all CDI testing
methodologies have limitations. Although PCR detects more
patients with toxigenic C. difficile, it is more costly and does not
distinguish between active infection, persistent shedding after
infection or asymptomatic carriage. Thus, clinical discretion is
required to guide appropriate diagnosis and treatment,
regardless of the testing methodology used.
In conclusion, our findings highlight differences between 2ST
and PCR that are relevant to hospitals switching from toxin
EIA to more sensitive testing methodologies. PCR testing for
CDI significantly increased the proportion of patients testing
positive for CDI when compared with both toxin EIA and 2ST,
corresponding to significantly higher HO and CO CDI rates.
PCR was associated with reduced testing frequency and faster
time to positive results, which may have beneficial infection
control and clinical implications. Furthermore, negative results
of PCR, but not 2ST, were associated with a significant
reduction in empirical CDI treatment days compared with
negative toxin EIA results.
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